Invited commentary.
Stecker
Mark
M
Department of Neurology, Geisinger Medical Center, Danville, PA 17822, USA. mark_stecker@yahoo.com
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001929:Brain Edema / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D050792:Circulatory Arrest, Deep Hypothermia Induced / Q000009:adverse effects*; D003911:Dextrans / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D020925:Hypoxia-Ischemia, Brain / Q000209:etiology* / Q000378:metabolism / Q000473:pathology; D023421:Models, Animal; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015427:Reperfusion Injury / Q000209:etiology / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D012462:Saline Solution, Hypertonic / Q000008:administration & dosage / Q000627:therapeutic use*; D012965:Sodium Chloride / Q000008:administration & dosage / Q000627:therapeutic use*; D034421:Sus scrofa
D003911:Dextrans; D018696:Neuroprotective Agents; D012462:Saline Solution, Hypertonic; C104375:hypertonic saline-dextran solution; D012965:Sodium Chloride